What is Alaunos Therapeutics, Inc.'s earnings per share (EPS)?

Alaunos Therapeutics, Inc. (TCRT) reported diluted earnings per share of -$2.20 for fiscal year 2025. This represents a 24.7% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

Alaunos Therapeutics, Inc. (TCRT) Financials

TCRT

FY2025 annual

Revenue $5K -50.0% YoY

Net Income -$4.2M +10.8% YoY

EPS (Diluted) -$2.20 +24.7% YoY

Free Cash Flow -$3.0M +40.3% YoY

Market Cap $2.3M as of Oct 8, 2026

Price / Sales 457x on $5K revenue, FY2025

Price / Earnings n/m net loss, so no earnings multiple, FY2025

Price / Book 3.5x on $652K equity, Q2 FY2026

A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Oct 8, 2026; every other figure is from the SEC filings on this page. Not financial advice.

Source SEC Filings (10-K/10-Q) Latest period Q2 FY2026, ended Jun 30, 2026 Reported Aug 14, 2026 Currency USD FYE December

Newest figures come from the 10-Q for Q2 FY2026, filed Aug 14, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the TCRT SEC filings page.

Alaunos Therapeutics, Inc. (TCRT) reported $5K in revenue for fiscal year 2025, down 50.0% from the prior fiscal year. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 15 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Rhea AI TCRT FY2025 2026-10-03

The business remains development-stage: negligible revenue sits beside $1.4M of R&D and recurring cash outflows funded partly through financing.

The improvement in operating cash flow from -$5.0M in FY2024 to -$2.9M in FY2025 was not driven by commercialization: revenue fell to $5K while R&D increased. Lower SG&A appears to have done more of the work, so the cash improvement reflects tighter spending rather than operating self-funding.

R&D intensity has changed sharply: spending fell from $25.0M in FY2022 to $1.4M in FY2025. Revenue was only $5K in FY2025, indicating a much smaller development profile rather than a revenue-generating operating model.

FY2025 financing provided $3.3M while operating activities consumed $2.9M, showing that reported cash needs were met externally rather than by operations. The 2.4x current ratio and 5.8 months of reported outflow describe near-term liquidity, but the balance sheet still depends on funding outside the business.

Financial Health Signals

Financial health score not available

Alaunos Therapeutics, Inc. does not currently provide enough eligible data for a peer-relative financial health score, so none is published. The signals and metrics below are current.

Altman Z-Score Distress

-438.97

Alaunos Therapeutics, Inc. scores -438.97, below the 1.81 distress threshold. The score is driven primarily by a large market capitalization ($2.3M) relative to total liabilities ($813K). This indicates elevated financial distress risk and warrants close attention to liquidity and debt levels.

Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.

Piotroski F-Score Partial

2/7

Alaunos Therapeutics, Inc. passes 2 of 7 computable financial strength tests (2 of the nine could not be computed from available data). 2 of 4 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution), neither operating efficiency signal passes.

Earnings Quality No Cash Backing

N/A

Alaunos Therapeutics, Inc. reported a net loss of $4.2M while operations used $2.9M of cash. With neither figure positive, the ratio between the two carries no quality signal.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue

Alaunos Therapeutics, Inc. generated $0 in revenue in Q2 2026.

EBITDA

-$943K

YoY+9.2%

QoQ+6.1%

Alaunos Therapeutics, Inc.'s EBITDA was -$943K in Q2 2026, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 9.2% from the same quarter a year earlier. Against the prior quarter it is up 6.1%.

Net Income

-$952K

YoY+9.4%

QoQ+5.4%

Alaunos Therapeutics, Inc. reported -$952K in net income in Q2 2026. This represents an increase of 9.4% from the same quarter a year earlier. Against the prior quarter it is up 5.4%.

EPS (Diluted)

-$0.41

YoY+34.9%

QoQ+30.5%

Alaunos Therapeutics, Inc. earned -$0.41 per diluted share (EPS) in Q2 2026. This represents an increase of 34.9% from the same quarter a year earlier. Against the prior quarter it is up 30.5%.

Cash & Balance Sheet

Cash & Debt

$124K

YoY-95.7%

QoQ-65.0%

5Y CAGR-72.4%

10Y CAGR-49.2%

Alaunos Therapeutics, Inc. held $124K in cash as of Q2 2026; long-term debt is not reported for that period.

Shares Outstanding

YoY+15.7%

QoQ+6.8%

5Y CAGR-58.9%

10Y CAGR-32.6%

Alaunos Therapeutics, Inc. had 3M shares outstanding in Q2 2026. This represents an increase of 15.7% from the same quarter a year earlier. Against the prior quarter it is up 6.8%.

Free Cash Flow

Not reported for Q2 2026.

Dividends Per Share

Not reported for Q2 2026.

Margins & Returns

Return on Equity

-146.0%

YoY-117.3pp

QoQ-67.9pp

Alaunos Therapeutics, Inc.'s ROE was -146.0% in Q2 2026, measuring profit generated per dollar of shareholder equity. This is down 117.3 percentage points from the same quarter a year earlier. Against the prior quarter it is down 67.9 percentage points.

Gross Margin

Not reported for Q2 2026.

Operating Margin

Not reported for Q2 2026.

Net Margin

Not reported for Q2 2026.

Capital Allocation

R&D Spending

$388K

YoY+109.7%

QoQ-9.1%

Alaunos Therapeutics, Inc. invested $388K in research and development in Q2 2026. This represents an increase of 109.7% from the same quarter a year earlier. Against the prior quarter it is down 9.1%.

Share Buybacks

Not reported for Q2 2026.

Capital Expenditures

Not reported for Q2 2026.

TCRT Income Statement

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

TCRT quarterly income statement

Metric	TTM	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K	FY1310-K	FY1210-K	FY1110-K
Revenue	N/A	$5K-50.0%	$10K+100.0%	$5K-99.8%	$2.9M+634.2%	$398K-60.2%	$1.0M	N/A	$146K-99.1%	$15.9M+131.7%	$6.9M	N/A	N/A	N/A	$800K+19.9%	$667K
R&D Expenses	N/A	$1.4M+276.5%	$362K-97.8%	$16.3M-34.9%	$25.0M-49.6%	$49.6M-5.8%	$52.7M+37.5%	$38.3M+12.3%	$34.1M-24.3%	$45.1M-71.4%	$157.8M+47.8%	$106.8M+226.5%	$32.7M-23.7%	$42.9M-48.6%	$83.4M+46.2%	$57.1M
SG&A Expenses	N/A	$2.9M-35.7%	$4.5M-63.5%	$12.2M-7.0%	$13.1M-52.3%	$27.6M-0.4%	$27.7M+41.7%	$19.5M-2.0%	$19.9M+34.6%	$14.8M+2.9%	$14.4M-18.5%	$17.6M+45.1%	$12.2M-22.3%	$15.7M-19.8%	$19.5M+30.3%	$15.0M
Operating Income	N/A	-$4.2M+12.2%	-$4.8M+86.0%	-$34.3M+2.4%	-$35.1M+54.7%	-$77.5M+3.5%	-$80.4M-38.9%	-$57.9M-7.3%	-$53.9M-0.8%	-$53.5M+67.6%	-$165.3M-37.6%	-$120.1M-176.1%	-$43.5M+24.6%	-$57.7M+43.5%	-$102.2M-43.1%	-$71.4M
EBITDA	N/A	-$4.2M+12.3%	-$4.8M+84.9%	-$32.0M+1.2%	-$32.3M+56.8%	-$75.0M+5.4%	-$79.2M-38.4%	-$57.2M-7.3%	-$53.3M-0.4%	-$53.1M+67.8%	-$165.0M-37.8%	-$119.7M-178.2%	-$43.0M+24.5%	-$57.0M+43.9%	-$101.5M-42.7%	-$71.1M
Interest Expense	N/A	N/A	$0-100.0%	$1.9M-39.1%	$3.2M+165.3%	$1.2M	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Income Tax	N/A	$0	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Net Income	N/A	-$4.2M+10.8%	-$4.7M0.0%	-$4.7M+87.6%	-$37.7M+52.1%	-$78.8M+1.5%	-$80.0M+32.1%	-$117.8M-121.8%	-$53.1M+2.2%	-$54.3M+67.1%	-$165.3M-37.6%	-$120.1M-277.9%	-$31.8M+44.3%	-$57.1M+40.6%	-$96.1M-50.7%	-$63.8M
EPS (Basic)	N/A	-$2.20+24.7%	-$2.92+86.7%	-$21.97-741.8%	-$2.61-605.4%	-$0.37+2.6%	-$0.38+45.7%	-$0.70-172.9%	$0.96+281.1%	-$0.53+59.8%	-$1.32	N/A	N/A	N/A	N/A	N/A
EPS (Diluted)	-$1.91	-$2.20+24.7%	-$2.92	-$21.97	-$2.61	-$0.37+2.6%	-$0.38+45.7%	-$0.70-172.9%	$0.96+281.1%	-$0.53+59.8%	-$1.32	N/A	N/A	N/A	N/A	N/A
Diluted Shares (Avg)	N/A	2M+21.7%	2M	2M	14M	214M+2.3%	210M+24.8%	168M+16.9%	144M+4.9%	137M+5.0%	130M	N/A	N/A	N/A	N/A	N/A

Metric	Q2'2610-Q	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q
Revenue	$0	$0-100.0%	N/A	$0	$0-100.0%	$2K+100.0%	N/A	$0
R&D Expenses	$388K+109.7%	$427K+23.1%	N/A	$469K+228.0%	$185K+2.8%	$347K+175.4%	N/A	$143K-96.1%
SG&A Expenses	$564K-34.0%	$585K-21.7%	N/A	$718K-28.7%	$854K-13.7%	$747K-53.8%	N/A	$1.0M-71.9%
Operating Income	-$952K+8.4%	-$1.0M+7.3%	N/A	-$1.2M-3.2%	-$1.0M+10.9%	-$1.1M+37.3%	N/A	-$1.1M+86.7%
EBITDA	-$943K+9.2%	-$1.0M+8.1%	N/A	-$1.2M-3.2%	-$1.0M+10.8%	-$1.1M+37.2%	N/A	-$1.1M+85.6%
Interest Expense	N/A	N/A	N/A	N/A	N/A	N/A	N/A	$0
Net Income	-$952K+9.4%	-$1.0M+6.2%	N/A	-$1.2M-2.8%	-$1.1M+6.9%	-$1.1M+36.2%	N/A	-$1.1M+86.7%
EPS (Basic)	-$0.41+34.9%	-$0.59+11.9%	-$0.36+21.7%	-$0.55+21.4%	-$0.63+11.3%	-$0.67+36.2%	-$0.46+90.6%	-$0.70+86.8%
EPS (Diluted)	-$0.41+34.9%	-$0.59+11.9%	-$0.36+21.7%	-$0.55+21.4%	-$0.63+11.3%	-$0.67	-$0.46	-$0.70
Diluted Shares (Avg)	2M+45.1%	2M+21.7%	N/A	2M+36.3%	2M+4.8%	2M	N/A	2M

Not reported in any period shown, so not listed: Cost of Revenue, Gross Profit, Income Tax.

TCRT Balance Sheet

TCRT quarterly balance sheet

Metric	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K	FY1310-K	FY1210-K	FY1110-K
Total Assets	$3.0M+7.7%	$2.8M-66.7%	$8.3M-87.3%	$64.9M-31.5%	$94.9M-35.2%	$146.3M+34.1%	$109.1M+14.8%	$95.1M-10.0%	$105.6M-0.7%	$106.3M-30.8%	$153.7M+239.8%	$45.2M-37.0%	$71.8M-14.0%	$83.4M-22.9%	$108.1M
Current Assets	$2.0M-27.8%	$2.8M-66.7%	$8.3M-84.6%	$53.8M-31.8%	$78.8M-39.6%	$130.6M+23.8%	$105.5M+25.2%	$84.3M-7.2%	$90.8M-13.4%	$104.9M-31.2%	$152.5M+246.0%	$44.1M-37.3%	$70.3M-12.4%	$80.3M-24.3%	$106.1M
Cash & Equivalents	$1.4M+26.9%	$1.1M-82.0%	$6.1M-84.5%	$39.1M-48.6%	$76.1M-33.9%	$115.1M+44.3%	$79.7M+29.2%	$61.7M-13.0%	$70.9M-12.5%	$81.1M-42.4%	$140.7M+228.8%	$42.8M-37.2%	$68.2M-7.0%	$73.3M-30.0%	$104.7M
Short-Term Investments	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0
Long-Term Investments	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0
Total Liabilities	$813K+17.5%	$692K-64.6%	$2.0M-92.6%	$26.4M-28.3%	$36.8M+64.6%	$22.4M+58.6%	$14.1M+48.7%	$9.5M-95.3%	$202.4M+10.2%	$183.6M+176.8%	$66.4M+482.2%	$11.4M-49.1%	$22.4M-36.0%	$35.0M-4.2%	$36.5M
Current Liabilities	$813K+17.5%	$692K-64.6%	$2.0M-91.9%	$24.2M+50.7%	$16.0M-12.7%	$18.4M+46.6%	$12.5M+32.1%	$9.5M-54.5%	$20.9M+31.9%	$15.8M-12.8%	$18.1M+67.4%	$10.8M+39.0%	$7.8M-58.7%	$18.9M+41.2%	$13.4M
Non-Current Liabilities	$0	$0	$0-100.0%	$2.2M-89.3%	$20.8M+419.8%	$4.0M+153.2%	$1.6M+39350.0%	$4K-100.0%	$181.6M+8.2%	$167.8M+248.0%	$48.2M+8361.4%	$570K-96.1%	$14.6M-9.4%	$16.1M-30.4%	$23.1M
Long-Term Debt	N/A	$0	$0	$0-100.0%	$16.3M	$0	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Equity	$2.2M+4.4%	$2.1M-67.3%	$6.3M-83.6%	$38.6M-33.6%	$58.1M-53.2%	$124.0M+30.5%	$95.0M+11.0%	$85.6M+188.4%	-$96.8M-25.2%	-$77.3M-188.5%	$87.4M+158.2%	$33.8M-31.5%	$49.4M+1.9%	$48.4M-32.3%	$71.6M
Retained Earnings	-$924.6M-0.5%	-$920.4M-0.5%	-$915.8M-4.0%	-$880.6M-4.5%	-$842.9M-10.3%	-$764.1M-11.7%	-$684.1M-20.8%	-$566.3M+20.5%	-$712.4M-8.3%	-$658.0M-33.5%	-$492.7M-32.2%	-$372.6M-9.3%	-$340.8M-20.1%	-$283.7M	N/A

Metric	Q2'2610-Q	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q
Total Assets	$1.5M-68.0%	$1.9M-11.2%	$3.0M+7.7%	$3.7M+4.9%	$4.7M+1.2%	$2.1M-64.9%	$2.8M-66.7%	$3.5M-81.7%
Current Assets	$666K-82.2%	$970K-9.1%	$2.0M-27.8%	$2.7M-24.4%	$3.7M-20.1%	$1.1M-82.3%	$2.8M-66.7%	$3.5M-72.4%
Cash & Equivalents	$124K-95.7%	$354K+11.0%	$1.4M+26.9%	$1.9M+15.2%	$2.9M+16.9%	$319K-92.3%	$1.1M-82.0%	$1.7M-85.9%
Short-Term Investments	$0	$0	$0	$0	$0	$0	$0	$0
Long-Term Investments	$0	$0	$0	$0	$0	$0	$0	$0
Total Liabilities	$864K-19.6%	$595K-44.0%	$813K+17.5%	$921K+11.5%	$1.1M+18.4%	$1.1M-14.4%	$692K-64.6%	$826K-85.1%
Current Liabilities	$864K-19.6%	$595K-44.0%	$813K+17.5%	$921K+11.5%	$1.1M+18.4%	$1.1M-14.4%	$692K-64.6%	$826K-82.3%
Non-Current Liabilities	$0	$0	$0	$0	$0	$0	$0	$0-100.0%
Long-Term Debt	N/A	N/A	N/A	N/A	N/A	N/A	$0	N/A
Total Equity	$652K-82.2%	$1.3M+21.7%	$2.2M+4.4%	$2.8M+2.9%	$3.7M-2.9%	$1.1M-77.9%	$2.1M-67.3%	$2.7M-80.4%
Retained Earnings	-$926.6M-0.4%	-$925.6M-0.4%	-$924.6M-0.5%	-$923.7M-0.4%	-$922.6M-0.4%	-$921.5M-0.3%	-$920.4M-0.5%	-$919.7M-1.3%

Not reported in any period shown, so not listed: Inventory, Accounts Receivable, Goodwill.

TCRT Cash Flow Statement

TCRT quarterly cash flow statement

Metric	TTM	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K	FY1310-K	FY1210-K	FY1110-K
Operating Cash Flow	-$2.7M	-$2.9M+42.3%	-$5.0M+83.5%	-$30.1M-3.1%	-$29.2M+52.4%	-$61.5M-7.8%	-$57.0M-39.6%	-$40.9M+17.4%	-$49.5M+9.5%	-$54.7M+6.3%	-$58.3M-583150.0%	-$10K+100.0%	-$36.6M+38.4%	-$59.5M+24.5%	-$78.8M-103.0%	-$38.8M
Depreciation & Amortization	N/A	$7K+250.0%	$2K-99.9%	$2.3M-16.1%	$2.8M+6.2%	$2.6M+130.2%	$1.1M+79.3%	$629K+9.4%	$575K+55.8%	$369K+27.2%	$290K-18.8%	$357K-22.7%	$462K-37.4%	$738K+12.2%	$658K+145.5%	$268K
Stock-Based Compensation	N/A	$796K+83.0%	$435K-84.5%	$2.8M-20.6%	$3.5M-67.3%	$10.8M+57.8%	$6.8M+7.7%	$6.3M-15.8%	$7.5M-10.9%	$8.5M0.0%	$8.5M+5.7%	$8.0M+68.6%	$4.7M+35.2%	$3.5M-28.1%	$4.9M+76.9%	$2.8M
Capital Expenditures	N/A	$98K	$0-100.0%	$197K-8.8%	$216K-93.5%	$3.3M-66.0%	$9.8M+3343.0%	$284K-38.1%	$459K-37.7%	$737K+33.8%	$551K+33.7%	$412K+113.5%	$193K+46.2%	$132K-91.5%	$1.6M+34.9%	$1.2M
Free Cash Flow	N/A	-$3.0M+40.3%	-$5.0M+83.6%	-$30.3M-3.0%	-$29.4M+54.5%	-$64.8M+3.0%	-$66.8M-62.4%	-$41.1M+17.6%	-$49.9M+9.9%	-$55.4M+5.9%	-$58.9M-13851.7%	-$422K+98.9%	-$36.8M+38.2%	-$59.6M+25.8%	-$80.4M-101.0%	-$40.0M
Investing Cash Flow	N/A	-$98K	$0-100.0%	$1.3M+797.4%	-$193K+94.2%	-$3.3M+66.0%	-$9.8M-3343.0%	-$284K+38.1%	-$459K+37.7%	-$737K-33.8%	-$551K	N/A	N/A	-$131K+91.6%	-$1.6M-34.9%	-$1.2M
Financing Cash Flow	N/A	$3.3M	$0+100.0%	-$18.1M-384.9%	$6.4M-75.3%	$25.8M-74.8%	$102.1M+72.6%	$59.1M+46.7%	$40.3M-11.0%	$45.3M+5848.6%	-$788K	N/A	N/A	$54.5M+11.3%	$49.0M-41.9%	$84.3M
Share Buybacks	N/A	N/A	N/A	$0-100.0%	$45K	$0	N/A	$653K-59.7%	$1.6M	$0-100.0%	$2K-94.1%	$34K-93.8%	$544K+9.2%	$498K-8.8%	$546K+99.3%	$274K

Metric	Q2'2610-Q	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q
Operating Cash Flow	-$300K+57.2%	-$1.0M-33.5%	-$552K+6.8%	-$844K-8.1%	-$701K+58.3%	-$772K+59.7%	-$592K+92.0%	-$781K+87.7%
Depreciation & Amortization	$9K	$8K	$7K+800.0%	$0	$0-100.0%	$0-100.0%	-$1K-100.4%	$0-100.0%
Stock-Based Compensation	$246K+33.7%	$141K+107.4%	N/A	$301K+276.3%	$184K+82.2%	$68K-60.5%	N/A	$80K-89.0%
Capital Expenditures	N/A	N/A	$1K	N/A	N/A	N/A	$0	$0-100.0%
Free Cash Flow	N/A	N/A	-$553K+6.6%	N/A	N/A	N/A	-$592K+92.0%	-$781K+87.7%
Investing Cash Flow	N/A	N/A	-$1K	N/A	N/A	N/A	$0-100.0%	$0-100.0%
Financing Cash Flow	N/A	N/A	$0	$0	N/A	N/A	$0	$0

Not reported in any period shown, so not listed: Dividends Paid, Share Buybacks.

TCRT Financial Ratios

Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

TCRT quarterly financial ratios

Metric	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K	FY1310-K	FY1210-K	FY1110-K
Operating Margin	-84500.0%	-48120.0%	-685340.0%	-1201.4%	-19484.7%	-8036.1%	N/A	-36921.9%	-336.4%	-2409.4%	N/A	N/A	N/A	-12771.1%	-10704.6%
Net Margin	-83520.0%	-46790.0%	-93580.0%	-1291.2%	-19786.7%	-7997.6%	N/A	-36381.5%	-341.7%	-2409.2%	N/A	N/A	N/A	-12016.5%	-9561.9%
Return on Equity	-194.0%+32.9pp	-226.8%-152.6pp	-74.2%+23.7pp	-97.9%+37.8pp	-135.6%-71.1pp	-64.5%+59.5pp	-124.0%-61.9pp	-62.1%	N/A	N/A	-137.5%-43.5pp	-93.9%+21.7pp	-115.6%+82.8pp	-198.4%-109.4pp	-89.1%
Return on Assets	-140.8%+29.0pp	-169.8%-113.2pp	-56.6%+1.5pp	-58.1%+24.9pp	-83.0%-28.4pp	-54.6%+53.3pp	-108.0%-52.1pp	-55.9%-4.4pp	-51.4%+104.0pp	-155.4%-77.3pp	-78.1%-7.9pp	-70.3%+9.3pp	-79.6%+35.7pp	-115.3%-56.3pp	-59.0%
Current Ratio	2.45-1.5x	3.98-0.2x	4.22+2.0x	2.23-2.7x	4.91-2.2x	7.11-1.3x	8.42-0.5x	8.89+4.5x	4.35-2.3x	6.63-1.8x	8.42+4.3x	4.07-5.0x	9.02+4.8x	4.26-3.7x	7.94
Debt-to-Equity	0.38+0.4x	0.000.0x	0.000.0x	0.00-0.3x	0.28+0.3x	0.00-0.1x	0.150.0x	0.11	N/A	N/A	0.76+0.4x	0.34-0.1x	0.45-0.3x	0.72+0.2x	0.51
Asset Turnover	0.000.0x	0.000.0x	0.000.0x	0.040.0x	0.000.0x	0.01	N/A	0.00-0.1x	0.15+0.1x	0.06	N/A	N/A	N/A	0.010.0x	0.01
FCF Margin	-59340.0%	-49710.0%	-606780.0%	-1007.8%	-16279.2%	-6679.1%	N/A	-34189.0%	-348.5%	-858.1%	N/A	N/A	N/A	-10048.9%	-5995.6%

Metric	Q2'2610-Q	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q
Operating Margin	N/A	N/A	N/A	N/A	N/A	-54600.0%	N/A	N/A
Net Margin	N/A	N/A	N/A	N/A	N/A	-53650.0%	N/A	N/A
Return on Equity	-146.0%-117.3pp	-78.1%+23.3pp	N/A	-41.3%0.0pp	-28.7%+1.2pp	-101.4%-66.4pp	N/A	-41.4%+19.6pp
Return on Assets	-62.8%-40.6pp	-53.4%-2.8pp	N/A	-31.1%+0.6pp	-22.2%+1.9pp	-50.6%-22.7pp	N/A	-31.8%+11.8pp
Current Ratio	0.77-2.7x	1.63+0.6x	2.45-1.5x	2.92-1.4x	3.48-1.7x	1.00-3.9x	3.98-0.2x	4.30+1.5x
Debt-to-Equity	1.33+1.0x	0.46-0.5x	0.38+0.4x	0.330.0x	0.29+0.1x	1.00+1.0x	0.000.0x	0.30-0.1x
Asset Turnover	0.000.0x	0.000.0x	N/A	0.000.0x	0.000.0x	0.000.0x	N/A	0.000.0x

Not reported in any period shown, so not listed: Gross Margin, FCF Margin.

Reported as filed but not readable as a share of revenue in the periods where the ratio runs further from zero than a revenue base allows; no change figure is given where either compared period is one of those: Operating Margin, Net Margin.

Similar Companies

Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it.

Company	Fiscal year	Revenue	Net income	Net margin	Market cap	Health score
Alaunos Therapeutics, Inc. TCRT	FY2025	$5K	-$4.2M	N/A	$2.3M	—
Aptevo Therapeutics Inc APVO	FY2025	N/A	-$26.0M	N/A	$3.3M	—
ADITXT INC ADTX	FY2025	$3K	-$43.1M	N/A	$34K	—
GRI Bio, Inc. GRI	FY2025	N/A	-$12.0M	N/A	$4.0M	—
Xenetic Biosciences, Inc. XBIO	FY2025	$3.0M	-$2.7M	-90.1%	$5.2M	66/100
Clearmind Medicine Inc. CMND	FY2025	N/A	-$3.9M	N/A	$3.3M	—

Where Alaunos Therapeutics, Inc. Ranks

Frequently Asked Questions

What is Alaunos Therapeutics, Inc.'s annual revenue?

Alaunos Therapeutics, Inc. (TCRT) reported $5K in total revenue for fiscal year 2025. This represents a -50.0% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

How fast is Alaunos Therapeutics, Inc.'s revenue growing?

Alaunos Therapeutics, Inc. (TCRT) revenue declined by 50.0% year-over-year, from $10K to $5K in fiscal year 2025.

Is Alaunos Therapeutics, Inc. profitable?

No, Alaunos Therapeutics, Inc. (TCRT) reported a net income of -$4.2M in fiscal year 2025.

What is Alaunos Therapeutics, Inc.'s EBITDA?

Alaunos Therapeutics, Inc. (TCRT) had EBITDA of -$4.2M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.

What is Alaunos Therapeutics, Inc.'s return on equity (ROE)?

Alaunos Therapeutics, Inc. (TCRT) has a return on equity of -194.0% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.

What is Alaunos Therapeutics, Inc.'s free cash flow?

Alaunos Therapeutics, Inc. (TCRT) recorded an outflow of $3.0M in free cash flow during fiscal year 2025. This represents a 40.3% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

What is Alaunos Therapeutics, Inc.'s operating cash flow?

Alaunos Therapeutics, Inc. (TCRT) recorded an outflow of $2.9M in operating cash flow during fiscal year 2025, representing cash used by core business activities.

What are Alaunos Therapeutics, Inc.'s total assets?

Alaunos Therapeutics, Inc. (TCRT) had $3.0M in total assets as of fiscal year 2025, including both current and long-term assets.

What are Alaunos Therapeutics, Inc.'s capital expenditures?

Alaunos Therapeutics, Inc. (TCRT) invested $98K in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.

How much does Alaunos Therapeutics, Inc. spend on research and development?

Alaunos Therapeutics, Inc. (TCRT) invested $1.4M in research and development during fiscal year 2025.

How many shares does Alaunos Therapeutics, Inc. have outstanding?

Alaunos Therapeutics, Inc. (TCRT) had 2M shares outstanding as of fiscal year 2025.

What is Alaunos Therapeutics, Inc.'s current ratio?

Alaunos Therapeutics, Inc. (TCRT) had a current ratio of 2.45 as of fiscal year 2025, which is generally considered healthy.

What is Alaunos Therapeutics, Inc.'s debt-to-equity ratio?

Alaunos Therapeutics, Inc. (TCRT) had a debt-to-equity ratio of 0.38 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is Alaunos Therapeutics, Inc.'s return on assets (ROA)?

Alaunos Therapeutics, Inc. (TCRT) had a return on assets of -140.8% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

What is Alaunos Therapeutics, Inc.'s P/E ratio?

Alaunos Therapeutics, Inc. (TCRT) has no price-to-earnings ratio at the moment: net loss, so no earnings multiple (FY2025). The market capitalization is $2.3M as of Oct 8, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

What is Alaunos Therapeutics, Inc.'s price-to-sales ratio?

Alaunos Therapeutics, Inc. (TCRT) trades at 457x sales, its market capitalization divided by revenue of $5K revenue, FY2025. The market capitalization is $2.3M as of Oct 8, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

How does Alaunos Therapeutics, Inc.'s liquidity compare with its operating cash outflow?

At the end of fiscal year 2025, Alaunos Therapeutics, Inc. (TCRT) held $1.4M in cash, cash equivalents and investments, and reported an operating cash outflow of $2.9M over that year. Dividing the one by the other, the reported balance equals about 6 months of the outflow reported that year. This is arithmetic over figures already filed, not a projection: it assumes nothing about future spending, financing or operations.

What is Alaunos Therapeutics, Inc.'s Altman Z-Score?

Alaunos Therapeutics, Inc. (TCRT) has an Altman Z-Score of -438.97, placing it in the Distress Zone (elevated bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.

What is Alaunos Therapeutics, Inc.'s Piotroski F-Score?

Alaunos Therapeutics, Inc. (TCRT) has a Piotroski F-Score of 2 out of 7 computable signals; 2 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are Alaunos Therapeutics, Inc.'s earnings high quality?

Alaunos Therapeutics, Inc. (TCRT) reported a net loss of $4.2M while operations used $2.9M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.